Cladribine Novaplus (cladribine) Disease Interactions
There are 3 disease interactions with Cladribine Novaplus (cladribine):
Antineoplastics (Includes Cladribine Novaplus) ↔ Infections
Severe Potential Hazard, High plausibility
Applies to: Infection - Bacterial/Fungal/Protozoal/Viral
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
- "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
- "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
- "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
Cladribine (Includes Cladribine Novaplus) ↔ Myelosuppression
Severe Potential Hazard, High plausibility
Applies to: Bleeding, Fever, Bone Marrow Depression/Low Blood Counts
Cladribine induces myelosuppression, primarily affecting lymphocytes and monocytes, however, neutropenia, anemia, and thrombocytopenia have been reported during cladribine therapy. Myelosuppressive effects are most notable the first month following therapy and may require red blood cell and/or platelet transfusions. Therapy with cladribine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.
- Fleischman RA, Croy D "Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia." Am J Hematol 48 (1995): 293
- Betticher DC, Fey MF, Rabaglio M, Cerny T, Hess U, Meier V, Stalder M, Zulian G "Cladribine and severe myelotoxicity." Lancet 342 (1993): 1369
- Juliusson G, Liliemark J "Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections." Blood 79 (1992): 888-94
Cladribine (Includes Cladribine Novaplus) ↔ Hepatic Dysfunction
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
The pharmacokinetic disposition of cladribine has not be fully assessed. The effect of hepatic impairment on the elimination of cladribine is not known. Therapy with cladribine should be administered cautiously in patient with existing or predisposition to compromised hepatic function. Clinical monitoring of hepatic function is recommended.
- Bryson HM, Sorkin EM "Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies." Drugs 46 (1993): 872-94
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
Cladribine Novaplus (cladribine) drug Interactions
There are 336 drug interactions with Cladribine Novaplus (cladribine)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.